Toyota Teams with Tencent, Nissan Joins Forces with Baidu in China AI Drive 
Warner Bros Discovery Dives Into Data-Driven Ad Business, Debuts Data Platform 
PUMA and Scuderia Ferrari HP Unveil Miami Limited Edition Collection 
Nestlé Crushes Two Million Perrier Drinks Due to Contamination 
Juventus Partners with Two Circles in Bid to Globalize Brand and Enhance Partnerships 
Remy Cointreau Surprises with Lesser Decline in Sales Thanks to China Boost 
McDonald's Korea Announces Price Hike Amid Record Revenue 
Shein Joins Facebook, Amazon in EU Digital Regulations Compliance 
GS25 Launches Limited-Edition Makgeolli ‘Seoul Silver’ in Korea 
PepsiCo Recalls Another Popular Soda Brand 
Binance Reassures Filipino Users Amid SEC App Removal Request, Urges Balanced Review by Google and Apple 
DeepL Unleashes AI-Powered Tool for Business Writing 
TikTok Vows to Fight US Ban After Biden Signed Bill 
Aramco Becomes FIFA’s 6th Global Partner Joining Adidas, Coca-Cola, Qatar Airways, Hyundai, and Visa 
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2017 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Operating Officer, will present at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017 at 11:30am ET. Mr. Knickerbocker will become President and Chief Executive Officer of Five Prime on January 1, 2018.
The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at http://investor.fiveprime.com/events.cfm or directly at https://cc.talkpoint.com/bmoc001/121417a_as/?entity=8_N6Q3JCG. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
CONTACT:
Derek Cole
Investor Relations Advisory Solutions
720-785-4497
[email protected]
